Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
clozapine, Quantity: 50 mg/mL
Pfizer Australia Pty Ltd
clozapine
Oral Liquid, suspension
Excipient Ingredients: povidone; sodium propyl hydroxybenzoate; purified water; sodium methyl hydroxybenzoate; xanthan gum; glycerol; monobasic sodium phosphate dihydrate; sodium hydroxide; hydrochloric acid; sorbitol solution (70 per cent) (crystallising)
Oral
100 mL
(S4) Prescription Only Medicine
Treatment with CLOPINE is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. Non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. Intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).
Visual Identification: A free flowing yellow suspension; Container Type: Bottle; Container Material: Glass Type III Coloured; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2008-05-16
WARNING: GASTROINTESTINAL HYPOMOTILITY WITH SEVERE COMPLICATIONS: Clozapine may cause slowing down or blockage of intestine function, causing reactions such as constipation; nausea with or without vomiting; tenderness or swelling of the abdomen, or bloating; gas/wind; foul-smelling breath; stomach pains/ spasms; leakage of diarrhoea or frequent and forceful bowel movements; bowel urges with no resulting movements; weight loss due to lack of appetite; lower back pain; pain or pressure in the rectum and bleeding from the rectum. These can lead to extremely severe outcomes. Your doctor must monitor intestine function before prescribing and during your therapy with Clopine. It is extremely important to immediately advise your doctor, coordinator, pharmacist, or any other health professio- nal, of any changes to your bowel movements. MYOCARDITIS/CARDIOMYOPATHY: Cases of myocarditis (heart inflammation) and cardiomyopathy (disease of heart muscles) have been reported in patients on clozapine, some being very severe. Please advise your doctor if you have, or previously had, any heart problems. Your doctor will also monitor for this. If you feel any symptoms such as chest pain, please speak to your doctor immediately. CLOPINE ® _clozapine_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about CLOPINE. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. THE INFORMATION IN THIS LEAFLET WAS LAST UPDATED ON THE DATE LISTED ON THE FINAL PAGE. MORE RECENT INFORMATION ON THE MEDICINE MAY BE AVAILABLE. YOU SHOULD ENSURE THAT YOU SPEAK TO YOUR PHARMACIST OR DOCTOR TO OBTAIN THE MOST UP TO DATE INFORMATION ON THE MEDICINE. Those updates may contain important information about the medicine and its use of which you should be aware. All medicines have risks and benefits. Your doctor has weighed the risks of you taking CLOPINE against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING T Read the complete document
Version: pfpcloia10222 Supersedes: pfpcloia10120 Page 1 of 25 AUSTRALIAN PRODUCT INFORMATION – CLOPINE ® (CLOZAPINE) WARNING _CLOZAPINE _ _INDUCED _ _GASTROINTESTINAL _ _HYPOMOTILITY:_ SEVERE GASTROINTESTINAL ADVERSE REACTIONS HAVE OCCURRED WITH THE USE OF CLOZAPINE RESULTING IN POTENTIAL OUTCOMES OF HOSPITALISATION, SURGERY AND DEATH (SEE SECTION 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, AND SECTION 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)). PRIOR TO INITIATING AND DURING TREATMENT OF CLOPINE, SCREEN FOR CONSTIPATION AND IF NECESSARY, MANAGE AS PER CURRENT CLINICAL GUIDELINES. _MYOCARDITIS/CARDIOMYOPATHY_: CASES OF MYOCARDITIS, SOME OF WHICH HAVE BEEN FATAL, AND CARDIOMYOPATHY HAVE BEEN REPORTED IN PATIENTS ON CLOZAPINE (SEE SECTION 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE AND SECTION 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)). IF MYOCARDITIS OR CARDIOMYOPATHY IS SUSPECTED, CLOZAPINE TREATMENT SHOULD BE STOPPED AND THE PATIENT IMMEDIATELY REFERRED TO A CARDIOLOGIST. GENERALLY, PATIENTS WITH A HISTORY OF CLOZAPINE-ASSOCIATED MYOCARDITIS OR CARDIOMYOPATHY SHOULD NOT BE RECHALLENGED WITH CLOZAPINE. 1. NAME OF THE MEDICINE Clozapine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CLOPINE ® 25 Each 25 mg tablet contains 25 mg clozapine. CLOPINE ® 50 Each 50 mg tablet contains 50 mg clozapine. CLOPINE ® 100 Each 100 mg tablet contains 100 mg clozapine. CLOPINE ® 200 Each 200 mg tablet contains 200 mg clozapine. CLOPINE ® Suspension Each 1 mL of suspension contains 50 mg clozapine. EXCIPIENTS WITH KNOWN EFFECT: _TABLETS:_ Contains Sugars (as lactose monohydrate). _SUSPENSION:_ sorbitol solution (70 per cent) (crystallising), sodium methyl hydroxybenzoate and sodium propyl hydroxybenzoate. For the full list of excipients, see Section 6.1 List of excipients. Version: pfpcloia10222 Supersedes: pfpcloia10120 Page 2 of 25 3. PHARMACEUTICAL FORM CLOPINE ® 25 – 25 mg tablets: Round, yellow, flat, beveled edge tablets engraved with ‘25’ over a pressure sensitive breakline on one face. The other face plain. Read the complete document